Fatemeh Haghighi, PhD
- PROFESSOR | Neuroscience
- PROFESSOR | Psychiatry
Research Topics:
Bioinformatics, Biostatistics, Blood-Brain Barrier, Chromatin, Depression, Epigenetics, Genetics, Genomics, Human Genetics and Genetic Disorders, Neurobiology, Neuroscience, Sleep Medicine, TranslationDr. Haghighi is a Professor of Neuroscience and the Director of the Laboratory of Medical Epigenetics at the Icahn School of Medicine at Mount Sinai. She obtained her PhD in Statistical Genetics in 2000 and went on to complete a postdoctoral fellowship in Computational Biology and Bioinformatics in 2004, both from Columbia University. Her research is focused on understanding how epigenetic mechanisms contribute to the risk of neurodevelopmental and neuropsychiatric disorders. Her studies have characterized regional and cell specific epigenetic neuronal profiles during human brain development important in understanding neuropathological alterations in depression and suicidal behavior. Dr. Haghighi is a recipient of the American Foundation for Suicide Prevention's Distinguished Investigator Award. She is also a Principle Investigator on awards from the National Institute of Health and the US Department of Veteran Affairs. Her work is highly cited, and featured in national and international scientific publications.
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS], Pharmacology and Therapeutics Discovery [PTD]Haghighi Laboratory, Neuro-Epigenetics
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Haghighi did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.